US Stock MarketDetailed Quotes
BRTX Biorestorative Therapies
- 1.480
- +0.035+2.42%
Close Nov 22 16:00 ET
- 1.461
- -0.019-1.28%
Post 16:11 ET
10.24MMarket Cap-1034P/E (TTM)
1.510High1.400Low55.50KVolume1.420Open1.445Pre Close81.38KTurnover1.09%Turnover RatioLossP/E (Static)6.92MShares3.67052wk High1.03P/B7.55MFloat Cap1.03052wk Low--Dividend TTM5.10MShs Float8.900Historical High--Div YieldTTM7.61%Amplitude1.030Historical Low1.466Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Biorestorative Therapies Stock Forum
BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data
5 minutes ago, 4:00 AM PST
Via GlobeNewswire
– Blinded preliminary data demonstrate a positive trend and clear signal in Primary and Secondary endpoints –
– Patient reported efficacy outcomes show a material decrease in pain and increase in function –
– If positive trends continue, Company confident that the Phase 2 trial will meet its Primary and Secondary end points -
...
MELVILLE, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it has received a provisional license from the New York State Department of Health (“NYSDOH”) for the pro...
BioRestorative Therapies Receives Expanded Tissue License From New York State Department of Health
BioRestorative Therapies Receives Patent Allowance for ThermoStem® Metabolic Disease Program
BioRestorative Therapies has received a Notice of Allowance from the Israel Patent Office for its ThermoStem® technology platform. This marks the 14th international patent outside the U.S. for this technology. The patent covers brown adipose derived stem cell (BADSC) aggregates, encapsulation systems, and treatment methods. The company believes ThermoStem®-based BA...
BioRestorative Therapies, Inc. (BioRestorative or BRTX), a company specializing in stem cell-based therapies, has announced that it received a notice of allowance from the Japanese Patent Office for patent application No. 2021-564135. This patent pertains to the com...
No comment yet